That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Imunon Inc (IMNN) progresses with pivotal Phase 3 trials while navigating financial hurdles and seeking strategic ...

Stacy Lindborg; President, Chief Executive Officer and Board Director; Imunon Inc. Presentation. Operator. Good morning. My name is Dave, and I will be your operator ...

Imunon, Inc. ( NASDAQ: IMNN) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive Officer Douglas ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

LiveOne Inc (LVO) is expected to report $-0.04 for 4Q. Lyell Immunopharma Inc (LYEL) is expected to report $-0.20 for 1Q. Macerich Co (MAC) is expected to report $-0.09 for 1Q. Mineralys Therapeutics ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...